- 1:8
- 1:4
Tazobactam and piperacillin API size was valued at USD 431.7 Million in 2023 and poised to grow at a CAGR of 2.1% during 2024-2030. The market value is changed due to the dynamic pricing of the tazobactam. The price of tazobactam API is USD 877.4 per kg. However, the demand for tazobactam and piperacillin was increasing over the forecast years due to the drug shortages in Europe and North America region. Qilu is the major supplier of tazobactam and piperacillin in the global market. However, the fire accident that happened in 2016, has created a significant impact on the availability of the API in the market due to which the company has lost a few of its customers where the competitor has taken an opportunity to enter into their customer’s supply chain for tazobactam API. Qilu Tianhe holds the highest market share of around 49.8% in tazobactam API production followed by Fuxiang with 25.3%. The market is a duopoly market dominated by Qilu and Fuxiang. Tazobactam is used mostly in combination with piperacillin. However, there are a few other molecules where the tazobactam combination used that includes Ceftazidime, Cefoperazone, and Ceftriaxone.In June 2022, the Piperacillin & Tazobactam API market in Europe showcased an increase on the back of improving demand with limited regional supply.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Bacterial diseases continue to be the leading cause of morbidity and mortality worldwide. Inadequate funding, subpar microbiology services, a lack of technical experts, and a need for epidemiological data to guide better preventive and treatment strategies all contribute to the rise in the burden of bacterial infections. Infectious diseases are prevalent in different parts of the world, regardless of developing or developed countries, and are heavily influenced by vulnerable populations, social inequality, economic imbalance, limited access to healthcare, and other factors. A high incidence of antimicrobial resistance (AMR) also coexists with this rise in the burden of bacterial illnesses.The global burden of infectious diseases is high, particularly in low- and lower-middle-income countries (LMICs). In contrast, non-communicable diseases are responsible for most deaths in upper-middle and high-income countries.
However, developed countries are still vulnerable to outbreaks of bacterial infections due to increased international travel. In 2019, approximately 7 million people died of infectious diseases, accounting for nearly 12% of all deaths globally. Furthermore, it has been estimated that 700,000 deaths occur each year globally due to drug-resistant organisms. If preventive and control measures are not taken, this number could rise to 10 million by 2050, with an economic loss of $100 trillion.Piperacillin/tazobactam is an effective combination antibiotic against a broad range of bacteria, including those that produce beta-lactamases. It is used to treat various infections, including lower respiratory tract infections, intra-abdominal infections, urinary tract infections, gynecological infections, skin and soft tissue infections, and fever in patients with neutropenia. In severe cases, piperacillin/tazobactam may be combined with an aminoglycoside antibiotic. Moreover, the demand for piperacillin/tazobactam API is increasing due to the increase in prevalence of infectious diseases.
The Tazobactam and Piperacillin API was valued at USD 431.7 Million in 2022 and projected to reach USD 503.69 million by 2029.
The Tazobactam and Piperacillin API market is poised to grow at a significant CAGR of 2.1% from 2024 to 2030
The key market players in the Tazobactam and Piperacillin API market are Fresenius Kabi, Qilu Pharmaceutical Co., Ltd., SUANFARMA, Otsuka Chemical Co.,Ltd., Jiangxi Fushine Pharmaceutical Co., Ltd., Aurobindo Pharma, Zhejiang Benfor Biotech Co.,Ltd, and Reyoung Pharmaceutical Co., Ltd
1.Executive Summary |
2.Global Tazobactam and Piperacillin API Market Introduction |
2.1.Global Tazobactam and Piperacillin API Market - Taxonomy |
2.2.Global Tazobactam and Piperacillin API Market - Definitions |
2.2.1.Type |
2.2.2.Application |
2.2.3.Region |
3.Global Tazobactam and Piperacillin API Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Tazobactam and Piperacillin API Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Tazobactam and Piperacillin API Market By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. 0.0472222222222222 |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. 0.0444444444444444 |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6.Global Tazobactam and Piperacillin API Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Injection |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Others |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7.Global Tazobactam and Piperacillin API Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8.North America Tazobactam and Piperacillin API Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.0.0472222222222222 |
8.1.2.0.0444444444444444 |
8.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Injection |
8.2.2.Others |
8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9.Europe Tazobactam and Piperacillin API Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.0.0472222222222222 |
9.1.2.0.0444444444444444 |
9.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Injection |
9.2.2.Others |
9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
10.Asia Pacific (APAC) Tazobactam and Piperacillin API Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.0.0472222222222222 |
10.1.2.0.0444444444444444 |
10.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Injection |
10.2.2.Others |
10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11.Middle East and Africa (MEA) Tazobactam and Piperacillin API Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.0.0472222222222222 |
11.1.2.0.0444444444444444 |
11.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Injection |
11.2.2.Others |
11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12.Latin America Tazobactam and Piperacillin API Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.0.0472222222222222 |
12.1.2.0.0444444444444444 |
12.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Injection |
12.2.2.Others |
12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Fresenius Kabi |
13.2.2.Qilu Pharmaceutical Co., Ltd. |
13.2.3.SUANFARMA |
13.2.4.Otsuka Chemical Co.,Ltd. |
13.2.5.Jiangxi Fushine Pharmaceutical Co., Ltd. |
13.2.6.Aurobindo Pharma |
13.2.7.Zhejiang Benfor Biotech Co.,Ltd |
13.2.8.Reyoung Pharmaceutical Co., Ltd |
14. Research Methodology |
15. Appendix and Abbreviations |